Combination therapy with bevacizumab and a CCR2 inhibitor for human ovarian cancer: An in vivo validation study.

Tianyue Zhai Takashi MitamuraLei WangShimpei I KubotaMasaaki MurakamiShinya TanakaHidemichi Watari

Published in: Cancer medicine (2023)

BEV/CCR2i showed a sustained anticancer immunity-independent effect in human ovarian cancer that was more significant in serous carcinoma than in clear cell carcinoma.

Keyphrases

combination therapy
endothelial cells
induced pluripotent stem cells
dendritic cells
high grade
regulatory t cells